Allergan PLC. (AGN) Director Christopher J. Coughlin Buys 10,000 Shares of Stock

Allergan PLC. (NYSE:AGN) Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction dated Tuesday, December 5th. The shares were bought at an average cost of $163.30 per share, for a total transaction of $1,633,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Allergan PLC. (NYSE:AGN) traded up $1.20 during trading on Wednesday, reaching $165.48. 889,151 shares of the company’s stock traded hands, compared to its average volume of 2,931,912. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. The stock has a market capitalization of $55,508.12, a PE ratio of 10.82, a PEG ratio of 1.12 and a beta of 1.11. Allergan PLC. has a twelve month low of $160.07 and a twelve month high of $256.80.

Allergan (NYSE:AGN) last issued its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.06 by $0.09. The business had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.32 earnings per share. research analysts forecast that Allergan PLC. will post 16.28 earnings per share for the current fiscal year.

Allergan declared that its board has authorized a stock repurchase plan on Monday, September 25th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be issued a dividend of $0.70 per share. The ex-dividend date is Thursday, November 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.69%. Allergan’s payout ratio is -12.44%.

A number of brokerages have recently weighed in on AGN. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $250.00 target price (down previously from $277.00) on shares of Allergan in a research note on Thursday, October 19th. They noted that the move was a valuation call. J P Morgan Chase & Co set a $275.00 target price on shares of Allergan and gave the company a “buy” rating in a research note on Sunday, October 22nd. BidaskClub lowered shares of Allergan from a “sell” rating to a “strong sell” rating in a research note on Friday, August 25th. Mizuho reaffirmed a “buy” rating and set a $267.00 target price on shares of Allergan in a research note on Monday, September 25th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $258.00 target price on shares of Allergan in a research note on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. Allergan presently has a consensus rating of “Buy” and a consensus price target of $244.47.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGN. Howard Hughes Medical Institute bought a new stake in Allergan during the second quarter valued at approximately $103,000. Cable Hill Partners LLC grew its position in Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after buying an additional 370 shares during the period. Rockefeller Financial Services Inc. grew its position in Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after buying an additional 400 shares during the period. Jacobi Capital Management LLC grew its position in Allergan by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the period. Finally, Massey Quick & Co. LLC grew its position in Allergan by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after buying an additional 385 shares during the period. 81.34% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2017/12/06/allergan-plc-agn-director-christopher-j-coughlin-buys-10000-shares-of-stock.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply